Hill-Rom picks up patient positioning player Tridien Medical

Coral Springs, FL

Hill-Rom subsidiary Comfort Holdings has acquired all outstanding shares of Tridien Medical, which makes patient positioning devices and support surfaces. The deal will help Hill-Rom reduce costs and improve margins, the company said.

The deal will help Hill-Rom reduce costs by allowing it to “insource a significant supply chain function,” according to an SEC filing. Financial details were not disclosed.

While Hill-Rom is best known for its hospital beds, support surfaces and mattresses, it also markets surgical equipment, including scalpels and surgical positioning tools, as well as respiratory care devices, such as a vest-based airway clearance system.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Coral Springs, FL-based Tridien’s products include powered alternating pressure mattresses and nonpowered mattresses that adjust to a patient’s weight and/or position, mattresses that distribute a patient’s weight evenly to prevent pressure ulcers, and a mattress that alternates pressure to treat pressure ulcers.

In June last year, Hill-Rom announced it would acquire Welch Allyn for $2 billion. The deal saw Hill-Rom picking up patient-oriented diagnostics and monitoring devices, which allowed the company to round out its offerings and become “an even more relevant partner to acute care providers,” CEO John Greisch said at the time.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.